Publicaciones científicas

113 Publicaciones científicas disponibles

  • International Myeloma Working Group Consensus Recommendations on Imaging in Monoclonal Plasma Cell Disorders

    1 de junio de 2020 | Revista: The Lancet. Oncology

    Jens Hillengass  1 , Saad Usmani  2 , S Vincent Rajkumar  3 , Brian G M Durie  4 , María-Victoria Mateos  5 , Sagar Lonial  6 , Cristina Joao  7 , Kenneth C Anderson  8 , Ramón García-Sanz  9 , Eloísa Riva  10 , Juan Du  11 , Niels van de Donk  12 , Jesús G Berdeja  13 , Evangelos Terpos  14 , Elena Zamagni  15 , Robert A Kyle  16 , Jesús San Miguel  17 , Hartmut Goldschmidt  18 , Sergio Giralt  19 , Shaji Kumar  20 , Noopur Raje  21 , Heinz Ludwig  22 , Enrique Ocio  5 , Rik Schots  23 , Hermann Einsele  24 , Fredrik Schjesvold  25 , Wen-Ming Chen  26 , Niels Abildgaard  27 , Brea C Lipe  28 , Dominik Dytfeld  29 , Baldeep Mona Wirk  30 , Matthew Drake  31 , Michele Cavo  15 , Juan José Lahuerta  32 , Suzanne Lentzsch  33

    (1) Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
    (2) Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA.
    (3) Division of Hematology, Department of Internal Medicine and Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
    (4) Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA.
    (5) Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain.
    (6) Emory University Medical School, Atlanta, GA, USA.
    (7) Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.
    (8) Dana-Farber Cancer Institute, Boston, MA, USA.
    (9) Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
    (10) Department of Hematology, Hospital de Clinicas, Montevideo, Uruguay.
    (11) Department of Hematology, Changzhen Hospital, Shanghai, China.
    (12) VU University Medical Center Amsterdam, Amsterdam, Netherlands.
    (13) Sarah Cannon Research Institute, Nashville, TN, USA.
    (14) Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
    (15) University of Bologna, Bologna, Italy.
    (16) Department of Laboratory Medecine and Pathology, Mayo Clinic, Rochester, MN, USA.
    (17) Clinica Universitaria de Navarra, CIMA, Pamplona, Spain.
    (18) University Hospital Heidelberg, National Center for Tumor diseases Heidelberg, Heidelberg, Germany.
    (19) Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
    (20) Department of Hematology, Mayo Clinic, Rochester, MN, USA.
    (21) Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
    (22) Department of Medicine I, Wilhelminenspital Der Stadt Wien, Vienna, Austria.
    (23) Department of Clinical Hematology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
    (24) Universitätsklinik Würzburg, Würzburg, Germany.
    (25) Oslo Myeloma Center, Oslo University Hospital; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
    (26) Department of Hematology and Oncology, Beijing Chaoyang Hospital, Beijing, China.
    (27) Department of Hematology, Syddansk Universitet, Odense, Denmark.
    (28) Departments of Medicine and Hematology and Oncology, University of Rochester, Rochester, NY, USA.
    (29) Karol Marcinkowski University of Medical Sciences, Poznan, Poland.
    (30) Department of Hematology and Oncology, Boston University, Boston, MA, USA.
    (31) Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine and Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
    (32) Department of Hematology, Grupo Español di Mieloma, Hospital Universitario, Madrid, Spain.
    (33) Department of Medicine, Division of Hematology and Oncology, Columbia University, New York, NY, USA.


  • A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    14 de mayo de 2020 | Revista: Leukemia

    Mikhael J (1,2), Richter J (3,4), Vij R (5), Cole C (6,7), Zonder J (8), Kaufman JL (9), Bensinger W (10), Dimopoulos M (11), Lendvai N (12,13), Hari P (14), Ocio EM (15), Gasparetto C (16), Kumar S (17), Oprea C (18), Chiron M (18), Brillac C (18), Charpentier E (19), San-Miguel J (20), Martin T (21).

    (1) Mayo Clinic, Scottsdale, AZ, USA.
    (2) Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
    (3) Hackensack University Medical Center, Hackensack, NJ, USA.
    (4) Mount Sinai Hospital, New York, NY, USA.
    (5) Washington University School of Medicine, St. Louis, MO, USA.
    (6) University of Michigan, Ann Arbor, MI, USA.
    (7) Michigan State University, East Lansing, MI, USA.
    (8) Karmanos Cancer Institute, Detroit, MI, USA.
    (9) Winship Cancer Institute of Emory University, Atlanta, GA, USA.
    (10) Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    (11) National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
    (12) Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
    (13) Janssen Pharmaceuticals, Titusville, NJ, USA.
    (14) Medical College of Wisconsin, Milwaukee, WI, USA.
    (15) Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
    (16) Duke University Medical Center, Durham, NC, USA.
    (17) Mayo Clinic, Rochester, MN, USA.
    (18) Sanofi Oncology R&D, Vitry/Alfortville, France.
    (19) Sanofi Genzyme Oncology, Cambridge, MA, USA.
    (20) Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
    (21) University of California at San Francisco, San Francisco, CA, USA.


  • Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma

    30 de abril de 2020 | Revista: Haematologica

    San-Miguel J (1), Usmani SZ (2), Mateos MV (3), van de Donk NWCJ (4), Kaufman JL (5), Moreau P (6), Oriol A (7), Plesner T (8), Benboubker L (9), Liu K (10), Hellemans P (11), Masterson T (12), Clemens PL (12), Luo M (12), Farnsworth A (13), Nahi H (14), Chari A (15).

    (1) Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain.
    (2) Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
    (3) University Hospital of Salamanca/IBSAL, Salamanca, Spain.
    (4) Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.
    (5) Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    (6) University Hospital of Nantes, Nantes, France.
    (7) Institut Català d'Oncologia, HGTiP, Barcelona, Spain.
    (8) Vejle Hospital and University of Southern Denmark, Vejle, Denmark.
    (9) Service d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau,Tours, France.
    (10) Janssen Research and Development, LLC, Raritan, NJ, USA.
    (11) Janssen Research and Development, Beerse, Belgium.
    (12) Janssen Research and Development, LLC, Spring House, PA, USA.
    (13) Janssen Research and Development, LLC, High Wycombe, United Kingdom.
    (14) Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden.
    (15) Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA.


  • Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma

    23 de abril de 2020 | Revista: Blood

    Perez C (1), Botta C (2), Zabaleta A (3), Puig N (4), Cedena MT (5), Goicoechea I (6), Alameda D (7), San-José Enériz E (8), Merino J (9), Rodriguez-Otero P (7), Maia CADS (6), Alignani D (10), Maiso P (7), Manrique I (11), Lara-Astiaso D (11), Vilas-Zornoza A (12), Sarvide S (13), Riillo C (14), Rossi M (14), Rosiñol L (15) Oriol A (16), Blanchard MJ (17), Rios R (18), Sureda A (19), Martín Sánchez J (20), Martinez R (21), Bargay J (22), de la Rubia J (23), Hernandez Garcia MT (24), Martínez-López J (5), Orfao A (25), Agirre X (26), Prosper F (7), Mateos MV (27), Lahuerta JJ (5), Bladé J (28), San Miguel J (26), Paiva B (7).

    (1) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Pamplona, Na, Spain.
    (2) "Annunziata" Hospital of Cosenza, Cosenza, Italy.
    (3) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain.
    (4) Hospital Universitario de Salamanca, Salamanca, Spain.
    (5) Hospital Universitario 12 de Octubre, Madrid, Spain.
    (6) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Pamplona, Spain.
    (7) Clinica Universidad de Navarra, Pamplona, Spain.
    (8) Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (9) University of Navarra, Pamplona, Spain.
    (10) Centro de Investigacion Medica Alplicada. Universidad de Navarra., Pamplona, Spain.
    (11) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
    (12) Centro de Investigacion Medica Aplicada, Pamplona, Spain.
    (13) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain, pamplona, Spain.
    (14) Magna Graecia University, Catanzaro, Italy.
    (15) Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
    (16) ICO - Hosp Germans Trias i Pujol, Badalona, Spain.
    (17) Hospital Ramon y Cajal, madrid, Spain.
    (18) Hospital Universitario Virgen de las Nieves, Granada, Spain.
    (19) Institut Català d'Oncologia, Barcelona, Spain.
    (20) Hospital Universitario Virgen del Rocio, Sevilla, Spain.
    (21) Hospital Clinico San Carlos, Madrid, Spain.
    (22) Hospital Son LLatzer, Palma Mallorca, Spain.
    (23) School of Medicine and Dentistry, Catholic University of Valencia, Spain.
    (24) Hospital Universitario de Canarias, La Laguna. Tenerife, Spain.
    (25) University of Salamanca, Salamanca, Spain.
    (26) Universidad de Navarra, Pamplona, Spain.
    (27) University Hospital of Salamanca/IBSAL/Cancer Research Center, Salamanca, Spain.
    (28) Hospital Clínic i Provincial, Institut de Investicacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

No hay más publicaciones científicas

No hay más páginas para cargar